Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in ...

On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and ...

Aspen Neuroscience, Inc. has successfully completed dose escalation and the first two cohorts of patients in the ASPIRO study, an ANPD001 Phase 1/2a clinical trial in Parkinson's Disease (PD).

Additionally, the company plans to initiate Phase 2a trials for IMM-1-104 in combination with a BRAF inhibitor and with a checkpoint inhibitor in 2025. Monday IMRX closed at $2.01 or 2.8985% lower ...

In patients with cancer, HT-001, designed to address skin toxicities, elicited encouraging interim safety and efficacy ...

2025 update from its ongoing Phase 2a clinical trial. Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer ...

The Company is pleased with the progress of the trials, which proceed highly successful Phase 1 and Phase 2A trials which have met all primary and secondary endpoints which notably include an ...

SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Aspen Neuroscience, Inc. has successfully completed dose escalation and the first two cohorts of patients in the ASPIRO study, an ANPD001 Phase 1/2a clinical ...